Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Rau, Thomas (57214509568)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Self-rated health predicts adverse events during beta-blocker treatment: The CIBIS-ELD randomised trial analysis
    (2013)
    Lainscak, Mitja (9739432000)
    ;
    Farkas, Jerneja (25225081600)
    ;
    Inkrot, Simone (35784615000)
    ;
    Gelbrich, Götz (14119833600)
    ;
    Neskovic, Aleksandar N. (35597744900)
    ;
    Rau, Thomas (57214509568)
    ;
    Tahirovic, Elvis (24339336300)
    ;
    Töpper, Agnieszka (38863078500)
    ;
    Apostolovic, Svetlana (13610076800)
    ;
    Haverkamp, Wilhelm (7005423154)
    ;
    Herrmann-Lingen, Christoph (6603417225)
    ;
    Anker, Stefan D. (56223993400)
    ;
    Düngen, Hans-Dirk (16024171900)
    Background: Self-rated health (SRH) predicts outcome in patients with heart failure. Beta-blockers are known to improve health-related quality of life and reduce mortality in such patients. We aimed to evaluate the relation between SRH and adverse events during titration of beta-blockers in elderly patients with heart failure. Methods: The cardiac insufficiency bisoprolol study in the elderly (CIBIS-ELD) is a multicentre, double-blind trial, in which 883 patients aged ≥ 65 years with chronic heart failure (73 ± 6 years, 38% women, left ventricular ejection fraction [LVEF] 42% ± 14%) were randomised to bisoprolol or carvedilol. SRH was assessed at baseline and after 12 weeks, using a 5-grade descriptive scale: excellent, very good, good, fair, and poor. Results: Median SRH at baseline and follow-up was good, but more patients reported fair/poor SRH at baseline (36% vs. 30%, p = 0.012). Women, beta-blocker-naïve patients, patients in NYHA class III/IV and those with PHQ-9 score ≥ 12 were more likely to report fair/poor baseline SRH (p < 0.001 for all). During follow-up, SRH improved in 34% of patients and worsened in 8% (p < 0.001). Adverse events were experienced by 64% patients and 38% experienced > 1 adverse event or serious adverse event, with higher prevalence in lower SRH categories. In a multivariate logistic regression model, SRH, age, distance achieved on the 6-min walk test and LVEF > 45% predicted adverse events (p < 0.05 for all). Conclusions: SRH is an independent predictor of adverse events during titration of beta-blockers and correlates with the proportion and number of adverse events per patient. © 2011 Elsevier Ireland Ltd. All rights reserved.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback